JCB launches a special offer program in Hokkaido for inbound tourist to Japan
TOKYO, Sep 28, 2023 – (JCN Newswire) – The Campaign Website at “FUN! JAPAN” TOKYO,…
TOKYO, Sep 28, 2023 – (JCN Newswire) – The Campaign Website at “FUN! JAPAN” TOKYO,…
Hong Kong, Sept 28, 2023 – (ACN Newswire) – AEON Credit Service (Asia) Company Limited…
Hong Kong, Sept 28, 2023 – (ACN Newswire) – China’s largest platform-centric decision-making AI company[1]…
Hong Kong, Sept 28, 2023 – (ACN Newswire) – On September 12th, Apple’s annual fall…
Nine in ten US employees rate their mental health positively due to a balanced workload…
Proposed capital increase with preferential subscription rights, to be carried out in January 2024 to…
Strong H1 sales growth (+101%) and significant reduction in current operating loss (-78%) Generated YTD…
Revenue of €4.3 million in the first half of 2023, +4% compared with H1 2022…
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology…
Brighsun EV Group and 2U Chat have embarked on the mass production of one of…
BREXAFEMME Carton BREXAFEMME Blister Pack JERSEY CITY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) — SCYNEXIS,…
MALVERN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
LA JOLLA, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded…
LOS ANGELES–(BUSINESS WIRE)–Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) (“Faraday Future”, “FF” or “Company”), a…
ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and…
ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and…
VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or…
VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or…
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage…
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage…